Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1374)	12/24/2004 1:51:49 AM
From: rjk01	Read Replies (1) \| Respond to of 1386

Harry, so what I hear you saying is…: The CEO has to go! Pharmos' best hope is to partner their CB-2 analgesia platform From what you know about their pain platform how realistic it is to expect an offer from the big league? Last, I hate to put it on you but go back and read your answer to my inquiry about the management pre discovery shameless sell... Never mind that, I should have known better just a while ago the management of BPUR pulled the same sting on the shareholder (They were even bolder then Aviv and gad proclaiming a success while cashing in. we went from near 2 digit PPS to a few cents). I decided to hold for now despite the grim situation, please keep posting when/if you suspect a new development or shift in what might be the future outcome of this mess. Thanks. O one more thing: Aviv seem to be Oblivious not just to the shareholders but also to some first class dr’s and scientist who have been for many years supporting his company/intimate with the science. Is he immune to scrutiny? Does the board and the shareholder have any say in all that?